CN110431142A - 药理学活性的脂环族取代的吡唑并[1,5-a]嘧啶衍生物 - Google Patents

药理学活性的脂环族取代的吡唑并[1,5-a]嘧啶衍生物 Download PDF

Info

Publication number
CN110431142A
CN110431142A CN201880017859.XA CN201880017859A CN110431142A CN 110431142 A CN110431142 A CN 110431142A CN 201880017859 A CN201880017859 A CN 201880017859A CN 110431142 A CN110431142 A CN 110431142A
Authority
CN
China
Prior art keywords
methyl
formula
pyrazolo
carboxylic acid
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880017859.XA
Other languages
English (en)
Chinese (zh)
Inventor
I·博尔扎
V·罗曼
J·埃勒斯
Z·哈达地
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gerry Factory
Original Assignee
Gerry Factory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gerry Factory filed Critical Gerry Factory
Publication of CN110431142A publication Critical patent/CN110431142A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880017859.XA 2017-03-13 2018-03-12 药理学活性的脂环族取代的吡唑并[1,5-a]嘧啶衍生物 Pending CN110431142A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1700108 2017-03-13
HU1700108A HU231058B1 (hu) 2017-03-13 2017-03-13 Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
PCT/IB2018/051599 WO2018167630A1 (en) 2017-03-13 2018-03-12 PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
CN110431142A true CN110431142A (zh) 2019-11-08

Family

ID=89992389

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880017859.XA Pending CN110431142A (zh) 2017-03-13 2018-03-12 药理学活性的脂环族取代的吡唑并[1,5-a]嘧啶衍生物

Country Status (32)

Country Link
US (1) US11026946B2 (https=)
EP (1) EP3596080B1 (https=)
JP (1) JP7153662B2 (https=)
KR (1) KR20190127779A (https=)
CN (1) CN110431142A (https=)
AR (1) AR111176A1 (https=)
AU (1) AU2018235266B2 (https=)
BR (1) BR112019018843A2 (https=)
CA (1) CA3056185A1 (https=)
CL (1) CL2019002601A1 (https=)
CO (1) CO2019010120A2 (https=)
CY (1) CY1124708T1 (https=)
DK (1) DK3596080T3 (https=)
EA (1) EA038756B1 (https=)
EC (1) ECSP19072975A (https=)
ES (1) ES2893824T3 (https=)
GE (1) GEP20217256B (https=)
HR (1) HRP20211850T1 (https=)
HU (2) HU231058B1 (https=)
IL (1) IL268923A (https=)
LT (1) LT3596080T (https=)
MX (1) MX2019011000A (https=)
MY (1) MY195262A (https=)
PE (1) PE20191646A1 (https=)
PH (1) PH12019501968A1 (https=)
PL (1) PL3596080T3 (https=)
PT (1) PT3596080T (https=)
RS (1) RS62533B1 (https=)
SG (1) SG11201907864YA (https=)
SI (1) SI3596080T1 (https=)
UA (1) UA124783C2 (https=)
WO (1) WO2018167630A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116075514A (zh) * 2020-08-05 2023-05-05 吉瑞工厂 药理学活性的杂环取代的吡唑并[1,5-a]嘧啶衍生物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ797702A (en) 2017-03-13 2026-03-27 Lundbeck La Jolla Research Center Inc Dual magl and faah inhibitors
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔３，４－ｃ〕嗒衍生物
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN115872095A (zh) * 2022-11-28 2023-03-31 南通三鑫车灯配件有限公司 一种汽车车灯反光罩的生产线流转装置

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139240A1 (en) * 2006-05-25 2007-12-06 Korea Research Institute Of Chemical Technology 7-(3,4-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidine compounds, process for preparing thereof, and pharmaceutical composition for treating or preventing asthma, chronic obstructive pulmonary disease, arthritis, atopic dermatitis, tumor and degenerative brain diseases comprising the same
WO2009123986A1 (en) * 2008-03-31 2009-10-08 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
US20160304527A1 (en) * 2015-04-20 2016-10-20 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use
WO2017069270A1 (ja) * 2015-10-22 2017-04-27 大正製薬株式会社 含窒素縮合複素環化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100802863B1 (ko) 2004-03-02 2008-02-12 에프. 호프만-라 로슈 아게 불안증, 우울증 및 간질의 치료를 위한 ｇａｂａ 수용체리간드로서 4-(설파닐-피리미딘-4-일메틸)-모폴린 유도체및 관련 화합물
GB0512844D0 (en) 2005-06-23 2005-08-03 Novartis Ag Organic compounds
TWI648281B (zh) 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 含硫二環式化合物
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139240A1 (en) * 2006-05-25 2007-12-06 Korea Research Institute Of Chemical Technology 7-(3,4-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidine compounds, process for preparing thereof, and pharmaceutical composition for treating or preventing asthma, chronic obstructive pulmonary disease, arthritis, atopic dermatitis, tumor and degenerative brain diseases comprising the same
WO2009123986A1 (en) * 2008-03-31 2009-10-08 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
US20160304527A1 (en) * 2015-04-20 2016-10-20 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use
WO2017069270A1 (ja) * 2015-10-22 2017-04-27 大正製薬株式会社 含窒素縮合複素環化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116075514A (zh) * 2020-08-05 2023-05-05 吉瑞工厂 药理学活性的杂环取代的吡唑并[1,5-a]嘧啶衍生物

Also Published As

Publication number Publication date
MY195262A (en) 2023-01-11
CY1124708T1 (el) 2022-07-22
EP3596080B1 (en) 2021-09-01
CO2019010120A2 (es) 2019-10-09
ES2893824T3 (es) 2022-02-10
ECSP19072975A (es) 2019-11-30
AU2018235266A1 (en) 2019-10-17
PL3596080T3 (pl) 2022-01-31
LT3596080T (lt) 2021-11-25
JP2020510041A (ja) 2020-04-02
HU231058B1 (hu) 2020-04-28
RS62533B1 (sr) 2021-11-30
PT3596080T (pt) 2021-10-22
BR112019018843A2 (pt) 2020-04-14
CA3056185A1 (en) 2018-09-20
EA038756B1 (ru) 2021-10-14
IL268923A (en) 2019-10-31
WO2018167630A1 (en) 2018-09-20
KR20190127779A (ko) 2019-11-13
MX2019011000A (es) 2019-10-17
UA124783C2 (uk) 2021-11-17
AU2018235266B2 (en) 2021-09-30
SI3596080T1 (sl) 2022-01-31
AR111176A1 (es) 2019-06-12
SG11201907864YA (en) 2019-09-27
HUE056562T2 (hu) 2022-02-28
DK3596080T3 (da) 2021-11-15
EA201992127A1 (ru) 2020-02-06
CL2019002601A1 (es) 2020-01-24
JP7153662B2 (ja) 2022-10-14
HUP1700108A2 (en) 2018-09-28
US20200129515A1 (en) 2020-04-30
EP3596080A1 (en) 2020-01-22
PE20191646A1 (es) 2019-11-07
US11026946B2 (en) 2021-06-08
PH12019501968A1 (en) 2020-06-29
GEP20217256B (en) 2021-05-25
HRP20211850T1 (hr) 2022-03-04

Similar Documents

Publication Publication Date Title
CN110431142A (zh) 药理学活性的脂环族取代的吡唑并[1,5-a]嘧啶衍生物
EP3596079B1 (en) Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives
WO2017026516A1 (ja) イソチアゾール誘導体
TWI907472B (zh) 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物
KR101506778B1 (ko) 헤테로바이아릴-사이클로헥실-테트라아자벤조[e]아줄렌
TW202035403A (zh) 作為ｇａｂａａ ａ５受體調節子的雙環衍生物
JP2021519294A (ja) 複素環化合物及びその用途
TW202116755A (zh) 可用為幾丁質酶抑制劑的經取代的胺基三唑
KR20160003752A (ko) 피라지노[1,2-a]인돌 화합물들, 그들의 제조 및 의약에서의 이용
JP2001512124A (ja) 新規な２，３−ベンゾジアゼピン誘導体
WO2024207945A1 (zh) 作为aak1抑制剂的氮杂环类化合物
TW202122386A (zh) 經取代的1,3-苯基雜芳基衍生物及其在治療疾病中之用途
EA049144B1 (ru) ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ ЗАМЕЩЕННЫЕ ПО ГЕТЕРОЦИКЛИЧЕСКОМУ ФРАГМЕНТУ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА
OA19480A (en) Pharmacologically active alicyclicsubstituted pyrazolo [1,5-a] pyrimidine derivatives.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191108